MedTrace Logo

A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes

NCT00144144 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2006-07-14

No results posted yet for this study

Summary

The antihypertensive effect of the increased dose of angiotensin II receptor blocker (AII antagonist) is compared with that of the additional combined use of amlodipine in hypertensive patients with Type 2 diabetes mellitus, who have been treated with AII antagonist, the antihypertensive effect of which has been inadequate.

Conditions

Interventions

DRUG

Angiotensin II receptor antagonists, Calcium channel blocker

Sponsors & Collaborators

  • Japan Heart Foundation

    collaborator OTHER

  • Advanced-J

    lead OTHER

Principal Investigators

  • Ryuzo Kawamori, M.D. · Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2008-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144144 on ClinicalTrials.gov